We are building a Global Leader in the field of Repurposing Drugs for Orphan Diseases.
Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
SOM Biotech releases a new version of its proprietary drug repurposing process
Using the latest modular workflow technologies, SOM Biotech has released a new version of his […]
Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)
SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension […]
SOM Biotech at 2017 ASEBIO Investor Day
SOM Biotech was one of the presenting companies at 2017 ASEBIO Investor Day. ASEBIO Investor Day is […]
SOM Biotech invited at Chinese-Swiss Health Collaborations Forum
SOM Biotech was one of the companies invited to the Private Chinese-Swiss Investor Collaborations Forum […]
II Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne
La Compañía SOM Biotech estuvo presente en el II Workshop sobre Transferencia del Conocimiento Científico en la […]
SOM Biotech licenses its first product and expands to the United States
The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system […]
SOM Biotech at the 2017 New York Venture Summit
SOM Biotech was selected to present at the 2017 New York Venture Summit in front […]
21st Summer School of the University of Barcelona
Dr. Raúl Insa, SOM Biotech CEO, was invited to the 21st Summer School of the University […]
9th Summer School on Medicines
Dr. Raúl Insa, SOM Biotech CEO, was the invited speaker at Closing Session of 9th […]
SOM Biotech closed €2M funding round and opens €10M Series A
SOM Biotech closed €2M funding round on January 2017 where 18 international investors from 10 […]